Latest Tokyo Brief coverage on ONO PHARMACEUTICAL CO., LTD., tracking filings, financial news, and market signals from Japan.
TSE:4528
Ono Pharmaceutical will pay Biohaven $80mn upfront, $20mn in development milestones and a royalty of about 20% of sales for Asian rights to three IgG-degrading drugs, led by BHV-1300, now in phase 3 for Graves' disease.
Daito Pharmaceutical is folding into a new joint venture to absorb Kyorin's generic drug business while telling lawmakers that three straight years of annual price cuts have made its dominant Parkinson's disease tablet impossible to produce at a profit.
Current holdings disclosed by tracked funds.